Two urokinase dose regimens in native arterial and graft occlusions: initial results of a prospective, randomized clinical trial

Radiology. 1991 Mar;178(3):681-6. doi: 10.1148/radiology.178.3.1994402.

Abstract

The effects of two urokinase (UK) dose regimens on lysis time, lytic success, primary clinical success, and frequency of complications of peripheral thrombolysis were compared. Seventy-two intraarterial UK infusions were performed by means of standard catheter-directed infusion techniques in 63 patients with symptomatic peripheral arterial or bypass graft occlusions. Patients were prospectively randomized to high-dose (250,000 U/h for 4 hours and then 125,000 U/h) or low-dose (50,000 U/h) regimens. The mean time to complete lysis was 20.8, 26.0, 16.5, and 18.2 hours for the high-dose artery, low-dose artery, high-dose graft, and low-dose graft groups, respectively (P was not significant). Respective mean infusion durations were 27.1, 35.4, 22.2, and 25.3 hours. Clinical success was achieved in 65%-85% of cases. The frequency of complications was equivalent between groups, except for a higher frequency of minor bleeding complications in the high-dose group. The two urokinase dose regimens studied were equally effective in enabling peripheral thrombolysis.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Angiography
  • Extremities / blood supply
  • Female
  • Graft Occlusion, Vascular / diagnostic imaging
  • Graft Occlusion, Vascular / drug therapy*
  • Humans
  • Infusions, Intra-Arterial
  • Male
  • Middle Aged
  • Prospective Studies
  • Thrombolytic Therapy*
  • Thrombosis / diagnostic imaging
  • Thrombosis / drug therapy*
  • Time Factors
  • Urokinase-Type Plasminogen Activator / administration & dosage*
  • Urokinase-Type Plasminogen Activator / therapeutic use

Substances

  • Urokinase-Type Plasminogen Activator